<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002231</url>
  </required_header>
  <id_info>
    <org_study_id>004</org_study_id>
    <secondary_id>04/400-003-04</secondary_id>
    <nct_id>NCT00002231</nct_id>
  </id_info>
  <brief_title>Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers</brief_title>
  <official_title>GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Dose Escalation Study of GENEVAX-HIV Delivered Intramuscularly Using the Biojector 2000 in HIV Seronegative Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth-Lederle Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe to give GENEVAX-HIV, a new HIV vaccine, to&#xD;
      HIV-negative volunteers. This study will also look at how this vaccine affects the immune&#xD;
      system of these volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this open-label study, volunteers are given an intramuscular injection of GENEVAX-HIV&#xD;
      vaccine using the Biojector 2000. Safety measures and immune response are assessed&#xD;
      accordingly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <condition>HIV Seronegativity</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>APL 400-003</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        You may be eligible for this study if you:&#xD;
&#xD;
          -  Are 18 - 60 years old.&#xD;
&#xD;
          -  Are HIV-negative and in good health.&#xD;
&#xD;
          -  Are able to understand how infections such as HIV are spread.&#xD;
&#xD;
          -  Agree to use effective methods of birth control during the study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        You will not be eligible for this study if you:&#xD;
&#xD;
          -  Have hepatitis B or C.&#xD;
&#xD;
          -  Have any condition that may prevent you from completing the study.&#xD;
&#xD;
          -  Are allergic to bupivacaine, vaccines, or certain local anesthetics.&#xD;
&#xD;
          -  Have taken certain medications or have received certain therapies that may affect your&#xD;
             immune system.&#xD;
&#xD;
          -  Have an immune system disorder or have received therapy for an immune system disorder.&#xD;
&#xD;
          -  Have been exposed to HIV within 6 months prior to study entry.&#xD;
&#xD;
          -  Have received an experimental HIV vaccine or any other experimental treatment within&#xD;
             30 days prior to study entry.&#xD;
&#xD;
          -  Have received blood transfusions within 6 months prior to study entry.&#xD;
&#xD;
          -  Abuse alcohol or drugs or have an uncontrolled psychiatric disorder.&#xD;
&#xD;
          -  Are pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RR MacGregor</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Pennsylvania Med Ctr</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2000</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Injections, Intramuscular</keyword>
  <keyword>HIV Antibodies</keyword>
  <keyword>Immunity, Cellular</keyword>
  <keyword>AIDS Vaccines</keyword>
  <keyword>HIV Seronegativity</keyword>
  <keyword>Dose-Response Relationship, Immunologic</keyword>
  <keyword>Vaccines, DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

